Gusacitinib

Gusacitinib
Identifiers
	IUPAC name 2-[1-[4-[4-(4-hydroxypiperidin-1-yl)anilino]-5-oxo-6H-pyrimido[4,5-d]pyridazin-2-yl]piperidin-4-yl]acetonitrile;
CAS Number	1425381-60-7;
PubChem CID	71269142;
DrugBank	DB15670;
ChemSpider	71117451;
UNII	4801QYW816;
KEGG	D11676;
ChEMBL	ChEMBL4594275;
Chemical and physical data
Formula	C24H28N8O2
Molar mass	460.542 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1CN(CCC1CC#N)C2=NC3=C(C(=O)NN=C3)C(=N2)NC4=CC=C(C=C4)N5CCC(CC5)O;
	InChI InChI=1S/C24H28N8O2/c25-10-5-16-6-11-32(12-7-16)24-28-20-15-26-30-23(34)21(20)22(29-24)27-17-1-3-18(4-2-17)31-13-8-19(33)9-14-31/h1-4,15-16,19,33H,5-9,11-14H2,(H,30,34)(H,27,28,29); Key:NLFLXLJXEIUQDL-UHFFFAOYSA-N;

Gusacitinib (ASN002) is an investigational drug which acts as a pan-Janus kinase inhibitor, binding with similar affinity at JAK1, JAK2, JAK3 and TYK2, and also inhibiting spleen tyrosine kinase (SYK).^[1] It is taken orally and was developed for the treatment of eczema and dermatitis.^[2]^[3]^[4]

References

^ Raghuvanshi R, Bharate SB (January 2022). "Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections". Journal of Medicinal Chemistry. 65 (2): 893–921. doi:10.1021/acs.jmedchem.0c01467. PMID 33539089.
^ Bissonnette R, Maari C, Forman S, Bhatia N, Lee M, Fowler J, et al. (October 2019). "The oral Janus kinase/spleen tyrosine kinase inhibitor ASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate-to-severe atopic dermatitis: results from a randomized double-blind placebo-controlled study". The British Journal of Dermatology. 181 (4): 733–742. doi:10.1111/bjd.17932. PMC 6850605. PMID 30919407.
^ Zalewski A, Szepietowski JC (April 2023). "Topical and systemic JAK inhibitors in hand eczema - a narrative review". Expert Review of Clinical Immunology. 19 (4): 365–373. doi:10.1080/1744666X.2023.2174526. PMID 36708316.
^ Jimenez PA, Sofen HL, Bissonnette R, Lee M, Fowler J, Zammit DJ, et al. (August 2023). "Oral spleen tyrosine kinase/Janus Kinase inhibitor gusacitinib for the treatment of chronic hand eczema: Results of a randomized phase 2 study". Journal of the American Academy of Dermatology. 89 (2): 235–242. doi:10.1016/j.jaad.2023.04.027. PMID 37094653.

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.